insights_auto
Outlook: 78.1% bullish·3.1% bearish
Go to analysischevron_right
AZN:LON
AstraZeneca PLC (US)
GBX 13,916.00
arrow_upward
+0.40%(+56.00) 1D
Nov 3, 8:45:21 AM UTC · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
GBX 13,964.00
High
GBX 13,964.00
Low
GBX 13,870.00
Mkt. cap
215.59B
Avg. vol.
2.46M
Volume
124.60K
Dividend
1.72%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
26.37
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 5.28
Shares outstanding
1.55B
No. of employees
96K
Open
GBX 13,964.00
High
GBX 13,964.00
Low
GBX 13,870.00
Mkt. cap
215.59B
Avg. vol.
2.46M
Volume
124.60K
Dividend
1.72%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
26.37
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 5.28
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
BioPharma Dive
·
18 hours ago
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
Investing.com
·
19 hours ago
RBC Capital raises AstraZeneca stock price target on strong results
The Cryptonomist
·
21 hours ago
AstraZeneca share price jumps 7.02% to $186.65, with daily RSI at 75.14
Traders Union
·
1 day ago
Can robust earnings and new restructuring support AstraZeneca stock?
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com